Episode 205: An ominous biotech deal, vaccines for kids, & 'breakthrough' devices

Can buyouts be bad news? Why can't Novavax meet a deadline? And what does "breakthrough" actually mean? First, we delve into why the latest big biotech acquisition has ominous implications for the downtrodden sector. Then, STAT's Mario Aguilar joins us to explain how a well-intentioned FDA program is benefiting companies over patients. We also discuss the latest pandemic news, including the ongoing debate over boosters and yet another delay for Novavax.

Episode metadata supplied by the publisher feed · Published Apr 21, 2022

Embed this episode

Attribution link and audio player

Ready to play

Episode 205: An ominous biotech deal, vaccines for kids, & 'breakthrough' devices

0:00 32:59

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Readout Loud?

This episode is 32 minutes long.

When was this The Readout Loud episode published?

This episode was published on April 21, 2022.

Can I download this The Readout Loud episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!